本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 证券代码：300119 证券简称：瑞普生物 公告编号：2024-049 天津瑞普生物技术股份有限公司 关于 2022 年限制性股票激励计划部分限制性股票 回购注销完成暨股份变动的公告 特别提示： 1、本次回购注销 2022 年限制性股票激励计划已授予但尚未解除限售的限制 性股票数量合计 428,280 股，占回购注销前公司总股本的 0.0919%，涉及激励对 象 190 人。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次部分 限制性股票注销事宜已于 2024 年 9 月 2 日办理完成。 3、注销完成后，公司股份总数由 466,276,186 股减少至 465,847,906 股。 天津瑞普生物技术股份有限公司（简称"公司"）于 2024 年 6 月 11 日召开 的第五届董事会第十五次（临时）会议、第五届监事会第十二次（临时）会议和 2024 年 6 月 27 日召开的 2024 年第一次临时股东大会审议通过了《关于回购注 销 2022 年限制性股票激励计划部分限制性股票的议案》和《关于修改公 ...

证券代码：300119 证券简称：瑞普生物 天津瑞普生物技术股份有限公司投资者关系活动记录表 编号：2024-007 | --- | --- | --- | |----------------|--------------------------------------------------|-----------------------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 □ 媒体采访 | □ 分析师会议 √ 业绩说明会 | | 投资者关系活动 | □ 新闻发布会 | □ 路演活动 | | 类别 | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 投资者网上提问 | | | 人员姓名 | | | | 时间 | 2024 年 9 月 3 日 ( | 周二 ) 下午 13:30~16:30 公司通过全景网"投资者关系互动平台"（ https://ir.p5w.net ） | | 地点 | 采用网络远程 ...

天津瑞普生物技术股份有限公司 关于参加"2024 年度天津辖区上市公司半年报业绩说明会暨投 资者网上集体接待日"活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，天津瑞普生物技术股份有限公司（以下 简称"公司"）将参加由天津证监局、天津上市公司协会与深圳市全景网络有限 公司联合举办的"2024 年度天津辖区上市公司半年报业绩说明会暨投资者网上 集体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2024 年 9 月 3 日（周二）13:30-16:40。 届时公司董事长李守军先生、董事会秘书谢刚先生、财务负责人李改变女士 将在线就公司业绩、公司治理、发展战略、经营状况和可持续发展等投资者关心 的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 天津瑞普生物技术股份有限公司 董事会 二〇二四年八月二十八日 ...

注:上述质押股份未负担重大资产重组等业绩补偿义务。 2、股份累计质押情况 截至本公告披露日，李守军先生及其一致行动人所持股份质押情况如下： 证券代码：300119 证券简称：瑞普生物 公告编号：2024-047 天津瑞普生物技术股份有限公司 关于股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津瑞普生物技术股份有限公司（以下简称"公司"）近日接到控股股东、 实际控制人李守军先生，及持股 5%以上股东梁武先生的通知，获悉李守军先生、 梁武先生所持有公司的部分股份办理了质押手续，具体事项如下： 一、控股股东股份质押情况 | 股东名称 | 是否为 第一大 | 本次质押股 | | | | 占其所 | 占公 | | 是否为 | 用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 司总 | 是否为 | | | | | 股东及 | 份数量 | 质押日 | 质押到期日 质权人 | | 持股份 | 股本 | 限售股 | 补充质 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [2][4][7] Core Views - The pharmaceutical segment is under short-term pressure, with a 30% year-on-year decline in net profit attributable to the parent company in Q2. The company achieved a total revenue of 1.099 billion yuan in H1 2024, representing a year-on-year increase of 10.56%, while Q2 revenue was 566 million yuan, up 2.63% year-on-year. The net profit attributable to the parent company for H1 2024 was 159 million yuan, down 10.73% year-on-year, with Q2 net profit at 72 million yuan, down 26.56% year-on-year [2][5][6] - The company maintains high R&D investment, with a total of 96.71 million yuan in R&D expenses in H1 2024, accounting for 8.80% of revenue. New vaccines have received registration certificates, and the company plans to continue launching new products in the second half of the year [2][5] - The acquisition of Baoding Shoujun enhances the company's product matrix in foot-and-mouth disease vaccines, which is the largest single product in the pig vaccine market. This acquisition is expected to strengthen the company's competitive position in direct sales channels and contribute significant revenue growth [2][5] - The company has successfully launched its self-developed cat trivalent vaccine, "Ruimao Shu," with a cumulative shipment of over 1 million doses in H1 2024. The company is also actively preparing for the launch of other new pet medications [2][5] Financial Summary - For H1 2024, the company reported a gross margin of 48.52%, down 3.46 percentage points year-on-year, and a net profit margin of 15.27%, down 4.19 percentage points year-on-year. The decline in profitability is attributed to the low prices of raw materials and the sluggish downstream farming market [6][7] - The company forecasts net profits of 530 million yuan, 630 million yuan, and 650 million yuan for 2024, 2025, and 2026, respectively, with corresponding EPS of 1.1 yuan, 1.3 yuan, and 1.4 yuan. The current PE ratios are projected to be 11.0, 9.2, and 8.9 for the same years [2][7]

Investment Rating - Buy (Maintained) [1] Core Views - Revenue growth driven by pet sector, but veterinary drug profits under pressure [1] - H1 2024 revenue reached 1.099 billion yuan, up 10.56% YoY, while net profit attributable to shareholders decreased by 10.73% YoY to 159 million yuan [1] - Q2 2024 revenue was 566 million yuan, up 2.63% YoY, with net profit attributable to shareholders dropping 26.56% YoY to 72 million yuan [1] - Gross margin declined by 3.46 percentage points due to weak breeding market conditions and intense competition [1] - R&D investment increased to 96.71 million yuan, accounting for 8.80% of revenue, driving product innovation and market expansion [1] Business Performance - Poultry biological products sales reached 490 million yuan, up 14.88% YoY [1] - Pharmaceutical and API business revenue was 480 million yuan, up 2.29% YoY [1] - Pet sector revenue surged over 100% YoY to 34 million yuan, with strong sales of new cat triple vaccine (Rui Miao Shu) exceeding 1 million doses [2] - Expanded distribution channels with over 40 new partners and coverage of more than 5,700 hospital stores, including over 500 Ruipai pet hospitals [2] Financial Forecasts - EPS projected at 1.10, 1.35, and 1.61 yuan for 2024, 2025, and 2026, respectively [2] - Dynamic PE ratios estimated at 11x, 9x, and 7x for 2024, 2025, and 2026 [2] - Revenue growth rates forecasted at 24.02%, 21.89%, and 19.49% for 2024, 2025, and 2026 [3] - Net profit growth rates expected at 12.85%, 23.39%, and 18.88% for the same periods [3] R&D and Product Development - Obtained 8 new veterinary drug certificates, including vaccines and oral solutions [1] - Continued high R&D investment to enhance product quality and expand market share [1] - Future product pipeline includes rabies vaccine, cat quadruple mRNA vaccine, and oral deworming medications [2] Market and Industry Outlook - Pet healthcare market remains a blue ocean with significant growth potential [2] - Industry rating: In-line with the market, expected to perform within -5% to 5% of the relevant market index over the next 6 months [7]

Investment Rating - The report maintains a "Buy" rating for the company, with a current price of 11.85 yuan and a target price not specified for the next six months [1]. Core Insights - The company reported a revenue of 1.099 billion yuan for H1 2024, representing a year-on-year increase of 10.56%. However, the net profit attributable to shareholders decreased by 10.73% to 159 million yuan [1]. - The company is facing challenges due to rising costs in the breeding sector and competitive pressures in the animal health products market, leading to a decline in gross margin by 3.46 percentage points [1]. - The pet segment is showing strong growth, with revenue exceeding 34 million yuan, a growth rate of over 100% year-on-year, driven by new product launches and expanded distribution channels [2]. Summary by Sections Financial Performance - For H1 2024, the company achieved a revenue of 1.099 billion yuan, up 10.56% year-on-year, while the net profit attributable to shareholders was 159 million yuan, down 10.73% [1]. - In Q2 2024, revenue was 566 million yuan, a 2.63% increase year-on-year, but net profit fell by 26.56% to 72 million yuan [1]. - The gross margin decreased due to competitive pressures and cost management issues in the breeding sector [1]. Research and Development - R&D investment reached 96.71 million yuan in H1 2024, accounting for 8.80% of revenue. The company obtained eight new veterinary drug registration certificates [1]. - Continuous high R&D investment is expected to drive product upgrades and innovation, enhancing the company's competitive edge [1]. Pet Segment Growth - The pet segment's revenue grew over 100% year-on-year, with the newly launched cat trivalent vaccine achieving sales of over one million doses [2]. - The company is expanding its distribution network, covering over 5,700 hospital stores and more than 500 pet hospitals [2]. - Future product launches in the pet segment are anticipated to further enhance competitiveness and drive revenue growth [2]. Earnings Forecast - The company is projected to have an EPS of 1.1, 1.35, and 1.61 yuan for 2024, 2025, and 2026, respectively, with corresponding dynamic PE ratios of 11, 9, and 7 times [2].

证券代码：300119 证券简称：瑞普生物 公告编号：2024-043 天津瑞普生物技术股份有限公司 关于使用闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津瑞普生物技术股份有限公司（以下简称"公司""瑞普生物"）于2024年 8月22日召开了第五届董事会第十六次会议及第五届监事会第十三次会议，审议通 过了《关于使用闲置募集资金进行现金管理的议案》，同意公司及下属子公司在确 保不影响募集资金投资项目建设、不影响正常生产经营及确保资金安全的情况下， 使用额度不超过5.5亿元的闲置募集资金进行现金管理，在上述额度及期限内，资金 可以滚动使用。上述额度自董事会审议通过之日起12个月内有效，单笔理财产品期 限最长不超过12个月。 根据《深圳证券交易所创业板股票上市规则（2024年修订）》第7.1.2和7.1.3 条，及《公司章程》第41和110条等相关规定，本事项在公司董事会审批权限范围内， 无需提交公司股东大会审议。具体公告如下： 一、本次募集资金有关情况 经中国证券监督管理委员会《关于同意天津瑞普生物技术股份有限公司向特定 对象 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2024-042 天津瑞普生物技术股份有限公司 关于使用闲置自有资金购买理财产品的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1、投资品种：委托银行、证券公司、资产管理公司等专业理财机构对公司 及子公司闲置自有资金进行投资和管理或者购买相关理财产品，包括银行理财产 品、资产管理公司资产管理计划、证券公司发行的各类产品等。 2、投资额度：公司及子公司在任一时点使用闲置自有资金进行委托理财的 最高额度不超过人民币10.80亿元，其中：中、低风险理财产品最高额度不超过 人民币10亿元，中高风险理财产品最高额度不超过人民币8,000万元。 3、特别风险提示：公司进行委托理财可能面临的风险包括但不限于金融市 场波动风险、收益回报率不可预期风险、流动性风险、操作风险等。敬请投资者 注意投资风险。 天津瑞普生物技术股份有限公司（以下简称"公司"）于2024年8月22日召 开第五届董事会第十六次会议及第五届监事会第十三次会议，审议通过了《关于 使用闲置自有资金购买理财产品的议案》，为进一步提高公司 ...

天津瑞普生物技术股份有限公司 2024 年半年度 非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 汇总表第 1 页 | 其它关联资金 | 资金往来方名称 | 往来方与上市 公司的关联关 | 上市公司核算 | 2024 | 年期初往来资 | 2024 | 年半年度往来累计 | 2024 往来资金的利 | 年半年度 2024 | 年半年度偿 | 2024 | 年半年度末占 | 往来形成原因 | 往来性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 往来 | | | 的会计科目 | | 金余额 | | 发生金额（不含利息） | | | 还累计发生金额 | | 用资金余额 | | （经营性往来、 非 | | | | 系 | | | | | | 息(如有) | | | | | | 经营性往来） | | | 湖北龙翔药业科技股份 | 子公司 | 应收股利 | | 621.82 | | | | | | | 621.82 | 分红款 | 非经营性往来 | | | 有限公 ...